CD98/SLC3A2 Monoclonal antibody
CD98/SLC3A2 Monoclonal Antibody for WB, IHC, IF/ICC, ELISA
Host / Isotype
Mouse / IgG2a
Reactivity
human
Applications
WB, IHC, IF/ICC, ELISA
Conjugate
Unconjugated
CloneNo.
2B10F5
Cat no : 66883-1-Ig
Synonyms
Validation Data Gallery
Tested Applications
| Positive WB detected in | HeLa cells, MCF-7 cells, HepG2 cells, HT-29 cells, COLO 320 cells, Caco-2 cells, Jurkat cells |
| Positive IHC detected in | human renal cell carcinoma tissue, human colon cancer tissue, human cervical cancer tissue, human liver cancer tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
| Positive IF/ICC detected in | HeLa cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:5000-1:50000 |
| Immunohistochemistry (IHC) | IHC : 1:500-1:2000 |
| Immunofluorescence (IF)/ICC | IF/ICC : 1:400-1:1600 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Published Applications
| WB | See 6 publications below |
| IF | See 1 publications below |
Product Information
66883-1-Ig targets CD98/SLC3A2 in WB, IHC, IF/ICC, ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Cited Reactivity | human |
| Host / Isotype | Mouse / IgG2a |
| Class | Monoclonal |
| Type | Antibody |
| Immunogen | CD98/SLC3A2 fusion protein Ag7301 相同性解析による交差性が予測される生物種 |
| Full Name | solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2 |
| Calculated molecular weight | 68 kDa |
| Observed molecular weight | 85-94 kDa, 120-130 kDa |
| GenBank accession number | BC001061 |
| Gene symbol | CD98 |
| Gene ID (NCBI) | 6520 |
| RRID | AB_2882215 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Protein A purification |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Background Information
CD98 is a cell-surface heterodimer consisting of a heavy chain (CD98hc) and a light chain. CD98hc also interacts with certain integrin b-subunits to regulate cell migration, survival, proliferation, and adhesion/polarity. CD98hc is overexpressed on the cell surface of many cancers and increased CD98hc expression is associated with the development and progression of tumors.(PMID:25084765). This protein has 4 isoforms with the molecular mass of 58-71 kDa and can be detected 85-94 kDa due to glycosylation. The glycosylated CD98hc can links to a non-glycosylated light chain (~40 kDa) via a disulfide bond to form a heterodimeric CD98 antigen with molecular mass of 120-130 kDa (PMID: 14770309).
Protocols
| Product Specific Protocols | |
|---|---|
| WB protocol for CD98/SLC3A2 antibody 66883-1-Ig | Download protocol |
| IHC protocol for CD98/SLC3A2 antibody 66883-1-Ig | Download protocol |
| IF protocol for CD98/SLC3A2 antibody 66883-1-Ig | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
| Species | Application | Title |
|---|---|---|
J Extracell Vesicles Homosalate boosts the release of tumour-derived extracellular vesicles with protection against anchorage-loss property. | ||
Nat Commun Specificities of exosome versus small ectosome secretion revealed by live intracellular tracking of CD63 and CD9. | ||
Cancer Cell Int Matrix stiffness-dependent STEAP3 coordinated with PD-L2 identify tumor responding to sorafenib treatment in hepatocellular carcinoma | ||
Phytomedicine Identification of the target protein and molecular mechanism of honokiol in anti-inflammatory action | ||
Oncol Lett Hsa_circ_0050900 affects ferroptosis in intrahepatic cholangiocarcinoma cells by targeting hsa‑miR-605‑3p to regulate SLC3A2 | ||
Proc Natl Acad Sci U S A Activation of polyamine catabolism promotes glutamine metabolism and creates a targetable vulnerability in lung cancer |
